Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An announcement from Galera Therapeutics ( (GRTX) ) is now available.
On August 27, 2025, Galera Therapeutics and Clarus IV Galera Royalty AIV, L.P. amended their Royalty Agreement, reducing the royalty payable to Blackstone from a high single-digit percentage to four percent on sales of avasopasem and rucosopasem. Despite this amendment, Galera has previously suspended clinical development and commercial readiness efforts for these products, impacting its operational focus and market strategy.
Spark’s Take on GRTX Stock
According to Spark, TipRanks’ AI Analyst, GRTX is a Underperform.
Galera Therapeutics exhibits significant financial instability with consistent losses and negative equity, heavily impacting its overall score. The technical analysis indicates bearish market momentum, and the valuation is unattractive with a negative P/E ratio. The absence of positive earnings call data or corporate events further contributes to the poor stock performance outlook.
To see Spark’s full report on GRTX stock, click here.
More about Galera Therapeutics
Galera Therapeutics operates in the biotechnology industry, focusing on the development of novel therapeutics. The company’s primary products include avasopasem and rucosopasem, which are designed to address unmet medical needs.
Average Trading Volume: 67,789
Technical Sentiment Signal: Sell
Current Market Cap: $1.51M
See more insights into GRTX stock on TipRanks’ Stock Analysis page.